CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer By Ogkologos - August 14, 2025 631 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CT041-ST-01 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Emergency presentations: what are they, and what do they mean for... April 7, 2022 Helping Dogs—and Humans—with Cancer: NCI’s Comparative Oncology Studies July 10, 2019 The First Report from the Cancer Programme of the 100,000 Genomes... January 16, 2024 How to Talk About Cancer With Someone Who Has It August 24, 2021 Load more HOT NEWS EMA Publishes Guidance to Provide Key Methods and Good Regulatory Practices... Finding Purpose in Sharing Your Story: A Q&A With Esophageal Cancer... Patients Treated With Chemotherapy and B Cell–Targeting Agents Show Impaired Serological... EMA Recommends Extension of Indications for Pembrolizumab to Malignant Pleural Mesothelioma
